Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566988 · ClinicalTrials.gov registry record
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,604
- Enrollment target
NCT07566988 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,604 participants.
The verdict
NCT07566988 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,604 participants
- Enrollment target
Study Summary
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,604 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566988
The ClinicalTrials.gov registry entry for NCT07566988 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07566988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566988 about?
NCT07566988 is a clinical study titled "A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients". The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
What is the current status of trial NCT07566988?
This trial is currently completed. The enrollment target is 2,604 participants. The study started on 2024-10-25. Estimated completion is 2025-04-30.
Who is sponsoring clinical trial NCT07566988?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.